The detection of chimerism, residual molecular and cytogenetic disease following transplantation of peripheral blood stem cells (PBSCT) with a nonmyeloablative conditioning (n = 9) and the transplantation of highly purified CD34
PBSCT had the lowest rates of complete chimerism (CC) at 3 months after transplant. Only five of nine patients (55%) after CD34
؉ PBSCT and 19 of 33 patients (58%) after BMT achieved CC compared to 19 of 22 (86%) patients after PBSCT and seven of eight (88%) patients after PBSCT with reduced conditioning (P Ͻ 0.05). Bone Marrow Transplantation (2001) 27, 809-815. Keywords: CD34-PBSCT; PBSCT; reduced conditioning; molecular relapse Recently, new allogeneic transplant methods have been developed for the treatment of hematologic malignancies as an alternative treatment modality to the established methods of bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT). One of these new transplant methods is PBSCT after dose-reduced conditioning as recently published by Slavin and coworkers (PBSCT-reduced conditioning). 1 This transplant method is characterized by a reduced regimen-related organ toxicity thereby leading to better tolerability of the transplant procedure, which may in turn offer older patients or patients with serious comorbidities, who would otherwise not be eligible for transplant, a chance to undergo allogeneic transplantation.
A further new transplant method is the transplantation of highly purified CD34-positive blood stem cells (CD34 ϩ PBSCT). For this, the graft is not only highly enriched for hermatopoietic stem cells, but concomitantly depleted of CD3-positive T cells, which are responsible for the development of acute graft-versus-host disease post transplant. Generally it is accepted that reducing the incidence of moderate to severe acute GVHD is associated with a significant decrease of transplant-associated morbidity and mortality. On the other hand, according to the experience of T celldepleted BMT, 2 it can be expected that T cell-depleted PBSCT will be associated with an increased risk of leukemic relapse.
Relapse is considered to evolve from residual malignant cells that survive the pretransplant conditioning regimen and escape immune surveillance by allogeneic effector cells. Residual CML cells can be detected through the amplification of the unique M-bcr-abl fusion messenger (m) RNA transcripts as the molecular correlate of transcriptionally active Philadelphia-positive cells by the polymerase chain reaction (PCR). 3 The detection of bcr-ablmRNA in transplant patients is associated with an increased risk of CML relapse if repeated PCR assays show positive results later than 100 days post transplant. Sustained PCR negativity in the post-transplant course, on the other hand, is generally accepted to be associated with an excellent prognosis with regard to cytogenetic or hematologic disease recurrence. [3] [4] [5] In this prospective single-center study, we assessed chimerism by PCR of variable number of tandem repeats (VNTR) and minimal residual disease (MRD) as detected by regularly performed analyses of RT-PCR amplification of M-bcr-abl mRNA, as well as cytogenetic evaluations in patients with chronic phase (CP) of Ph-CML, ALL and AML with inversion (16) after CD34 ϩ PBSCT, PBSCTreduced conditioning, BMT and PBSCT.
Materials and methods
All patients undergoing transplantation for first CP of CML with genotypically HLA-identical sibling or partially HLAidentical extended family donors at the University Hospital of Essen between October 1994 and August 1999 were included in the present study. Two patients with ALL, another patient with AML and four further patients with CML in second CP, who were transplanted with PBSCTreduced conditioning, were included in the study to increase the number of study patients.
Approval for all aspects of this study had been obtained from the Institutional Review Board on Medical Ethics at the Essen University Hospital. Patients were preferentially transplanted with PBSCT with reduced conditioning if at least one of the following inclusion criteria was fulfilled: (1) a history of recent serious infectious complications pretransplant; (2) second transplants; (3) patient age over 60 years. Patients received a PBSCT after myeloablative conditioning according to previously published criteria. 6 Patients who underwent CD34 ϩ PBSCT were participating in a phase II study investigating the feasibility of highly purified CD34 ϩ cell transplantation without prophylactic post-transplant immunosuppression.
All patients who were discharged after transplantation were enrolled in our long-term follow-up program. Outpatient visits were performed at least at monthly intervals during the first 6 months and at 3-month intervals during the first 2 years post transplant. After 2 years, patients were usually seen annually.
Conditioning regimen
The conditioning regimen for patients who were scheduled for BMT or PBSCT, consisted of intravenous (i.v.) cyclophosphamide (60 mg/kg body weight (BW) per day ϫ 2) in combination with fractionated total body irradiation (TBI) (4 ϫ 2.5 Gy) delivered by a 60 cobalt source or oral busulfan (BU) (1 mg/kg BW every 6 h over 4 days) and i.v. cyclophosphamide (60 mg/kg BW per day ϫ 2).
Patients who were planned for CD34 ϩ PBSCT received a conditioning regimen with fractionated TBI, cyclophosphamide (60 mg/kg of BW per day ϫ 2) and thiotepa (5 mg/kg BW per day ϫ 2) with (n = 11) or without anti-T lymphocyte globulin (ATG) (10 mg/kg BW for 4 days) (n = 5). Patients who were scheduled for PBSCT with reduced conditioning received BU (1 mg/kg BW every 6 h over 2 days), fludarabine (30 mg/m 2 of body surface area over 5 days) and ATG (10 mg/kg BW for 4 days) (n = 9). Prophylaxis of acute GVHD consisted of i.v. methotrexate (15 mg/m 2 , day 1; 10 mg/m 2 , days 3, 6 and 11) in combination with continuous i.v. cyclosporine or cyclosporine alone. 7 All patients who received a CD34 ϩ PBSCT received no further GVHD prophylaxis. More details of patients' characteristics are shown in Table 1 .
Donors
One hundred and eight patients (75%) were genotypically HLA-identical with their respective donors, while 36 patients (25%) had a single class I-or II-antigen mismatch with regard to GVHD. Peripheral blood stem cells were mobilized by daily subcutaneous injections of 10 to 16 g rhG-CSF/kg donor body weight over 5 to 6 consecutive days. Details of stem cell aphereses performed in this study have been published previously. 8 Isolation of genomic DNA DNA was prepared from peripheral blood mononuclear cells (PB) obtained from the donor and recipient before the transplant using the phenol/chloroform method. After the transplant, DNA was extracted exclusively from the PB to allow determination of chimerism.
VNTR PCR
For PCR amplification we used specific primers designed to flank repeat units of the following human gene regions: APO-B and D1S80. For patients who could not be discriminated from their donors by their DNA type with either of these VNTR regions, we used geneprint STR III Triplex system and geneprint CTT Triplex system (Promega, Mannheim, Germany) each consisting of three different VNTR gene regions. PCR of STR III and FTT triplex system were performed according to the manufacturer's instruction. PCR of APO-B and D1S80 were performed as published earlier. 6 
Isolation of RNA and detection of BCR/ABL fusion products
RNA was prepared from PB, BM buffy coat cells, and K562 cells as a positive control. RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The cDNA synthesis reaction and nested PCR were performed as published earlier. 5 F = female; M = male; HLA = human leukocyte antigen; TBI = (fractioned) total body irradiation; Cyclo = cyclophosphamide; Thio = thiotepa; ATG = anti-T lymphocyte globulin; MTX = methotrexate; CP = chronic phase; CR = complete remission; GVHD = graft-versus-host disease according to grading of Glucksberg et al. 9 
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Cytogenetics
In all patients with CML the Philadelphia translocation could be demonstrated by bone marrow cytogenetic analysis prior to transplant.
Sensitivity of the PCR
The PCR assay for the detection of BCR/ABL transcript is reported to have a sensitivity of 0.0001%. 3 VNTR-PCR assays have a sensitivity of 1-5%. 6 
Definition of positive and negative PCR assays
The PCR assays were performed without knowledge of the patient's cytogenetic results, hematologic remission status or type of transplantation. A positive PCR test required a correct size bcr-abl PCR product as well as negative 'blank' and positive K562 cell amplifications. A negative assay required the absence of a bcr-abl PCR product as well as no amplification of the 'blank', but amplification of the K562 cell-positive control, and a successful GAPDH-PCR amplification. If a positive or negative control did not amplify as expected, the entire panel of patient samples done in that amplification 'batch' was discarded and repeated. The
Bone Marrow Transplantation date of the first positive PCR test was taken as the date of molecular relapse.
Definition of relapse
Hematological relapse was diagnosed on the basis of standard hematological criteria. Cytogenetic relapse was considered to be present if any Ph ϩ metaphases were detected without evidence of hematologic relapse.
Clinical outcome and statistical analysis
The diagnosis of acute and chronic GVHD was based on the characteristic clinical appearance of the symptoms of organ involvement. In case of doubt, the clinical diagnosis had to be confirmed by histological examinations of the suspected organ involvement whenever possible. Grading of acute or chronic GVHD followed the commonly accepted criteria. 9, 10 Estimates of chronic GVHD were based on patients surviving longer than 100 days post transplant. Transplant-related death was assumed if patients died post transplant without hematologic, cytogenetic or molecular evidence of disease recurrence.
Comparisons between continuous covariates were perfor-med by the two-tailed Wilcoxon rank-score test across strata. Differences between discrete covariates were compared by the two-tailed Fisher's exact test. Time to event estimates (Ϯ standard errors) were calculated by the product-limit method with right-censoring of subjects at the last time point at which they were at risk for a given event. 11, 12 Multivariate analyses with the time interval between transplantation and molecular relapse included age of donor and patient, gender constellation between recipient and donor, the occurrence of acute GVHD (grades 0 to I vs II to IV) or chronic GVHD, type of donor (HLA-identical sibling donor vs partially HLA-matched extended family donor), and the type of transplant as covariates. The independence of covariates with significance levels of less than 5% in univariate analysis was tested by proportional hazards general linear model (PHGLM) analyses using forward and backward selection processes. 11, 12 Maximal partial-likelihood estimates and estimates of conditional risk ratios (RR) and their 95% confidence limits (95% CL) were derived from regression analyses after adjustment for all significant covariates in the model.
Results
MRD-PCR results
The highest incidence of MRD was found in patients after CD34
ϩ PBSCT. According to the applied definition of MR, a repeatedly positive bcr-abl-PCR assay within a 4-week interval was detected in 10 of 16 (63%) patients after CD34
ϩ PBSCT compared to 27 of 69 (39%) patients after BMT. Patients after PBSCT or after PBSCT with reduced conditioning had a lower risk of MRD. In only three of 50 PBSCT 94 ± 5% Figure 1 Cumulative estimates to remain in molecular remission after transplantation of CD34 ϩ PBSCT, PBSCT with reduced conditioning, PBSCT and BMT in patients with CML (n = 135), ALL (n = 1) and AML (n = 1). The probability to remain in remission was 0% for patients after CD34
ϩ PBSCT, 51 Ϯ 7% for patients after BMT, whereas patients after PBSCT and PBSCT with reduced conditioning had a probability to remain in remission of 94 Ϯ 5% and 86 Ϯ 13%, respectively. Significant differences were found (P Ͻ 0.001) for BMT vs PBSCT and CD34
ϩ PBSCT vs BMT (P Ͻ 0.01).
(6%) patients after PBSCT (P Ͻ 0.001 compared to BMT and CD34
ϩ PBSCT) and one of seven (14%) patients after PBSCT with reduced conditioning was a MR detectable (not significant compared to BMT). The 2-year estimate (Ϯ standard error) of MR was 100% (Ϯ30%) for patients after CD34
ϩ PBSCT and 41 Ϯ 8% for patients after BMT (P Ͻ 0.03), whereas the risk of MR was 5 Ϯ 4% for patients after PBSCT (P Ͻ 0.001) and 20 Ϯ 18% for patients after PBSCT with reduced conditioning (NS) (Figure 1 ). In patients with a sibling donor transplant, the estimate of MR BMT 58 ± 8% CD34 + PBSCT 50 ± 17% Figure 2 Cumulative estimates to remain in cytogenetic remission after transplantation of CD34 ϩ PBSCT, PBSCT with reduced conditioning, PBSCT and BMT. The probability to remain in remission was 50 Ϯ 17% for patients after CD34
ϩ PBSCT, 58 Ϯ 8% for patients after BMT, whereas patients after PBSCT and PBSCT with reduced conditioning had a probability to remain in remission of 95 Ϯ 4% and 100%, respectively. Significant differences were found (P Ͻ 0.01) for BMT vs PBSCT and CD34 ϩ PBSCT vs PBSCT (P Ͻ 0.01).
CD34 + PBSCT 100%
BMT 65 ± 6%
PBSCT 63 ± 8% PBSCT red. conditioning 58 ± 20% Cumulative estimates of survival after transplantation of CD34 ϩ PBSCT, PBSCT with reduced conditioning, PBSCT and BMT. The probability of survival was 100% for patients after CD34
ϩ PBSC, 65 Ϯ 6% for patients after BMT, 63 Ϯ 8% for patients after PBSCT and 58 Ϯ 20% for patients after PBSCT with reduced conditioning. Significant differences were found (P Ͻ 0.05) for CD34 ϩ PBSCT vs BMT and PBSCT.
differs significantly from those of extended family donor transplants (35 of 82 (43%) vs six of 60 (10%) (P Ͻ 0.05)). Furthermore, the development of grade II-IV acute GVHD was associated with a decreased risk of MR (P Ͻ 0.03).
A MR was detected a median of 150 days after transplant (range 25-1245 days) in all patients. While a MR occurred at a median of 120 days after BMT (range 30-1245 days) and 90 days after PBSCT (range 62-98 days), it was detected significantly later with a median of 285 days in patients after CD34
ϩ PBSCT (range 25-495 days) (P Ͻ 0.05).
To evaluate interactions between different potential factors influencing MR, multivariate analysis, including acute and chronic GVHD as time-dependent covariates, was applied ( Table 2 ). This analysis confirmed that the relative risk of MR was about two times higher after CD34 ϩ PBSCT, whereas patients after PBSCT had an about eight times decreased risk of MR (P Ͻ 0.001) compared to patients after BMT. After adjustment for CD34 ϩ PBSCT and PBSCT, no other factor had a significant influence on the occurrence of MR.
Cytogenetic results
Cytogenetic relapse developed in three patients after CD34
ϩ PBSCT and two further patients had an engraftment failure but recovered with their autologous leukemic marrow (31%) compared to 21 of 69 patients (30%) after BMT (NS). In contrast, only two of 50 (4%) suffered from a cytogenetic relapse after PBSCT (P Ͻ 0.01) and none of the seven patients after PBSCT with reduced conditioning developed a cytogenetic relapse (NS). The probability to remain in cytogenetic remission for patients after CD34 ϩ PBSCT was 50 Ϯ 17% and for patients after BMT 58 Ϯ 8% (NS), compared to 100% in patients after PBSCT with reduced conditioning and 95 Ϯ 4% after PBSCT (P Ͻ 0.01) (Figure 2) .
Ten of 21 patients with a cytogenetic relapse after BMT and both relapsed patients after PBSCT progressed to a hematological relapse.
Clinical results
With a median follow-up of 33 months (range 1-76), 46 of 69 patients (67%) after BMT and 35 of 50 patients after ϩ PBSCT and PBSCT with reduced conditioning the median follow-up is 15 months. After this observation period six of nine patients after PBSCT with reduced conditioning and all 10 patients after CD34 ϩ PBSCT are alive (P Ͻ 0.05). This translates into a 3-year survival estimate of 65 Ϯ 6% and 63 Ϯ 8% for patients after BMT and PBSCT, respectively (NS). Patients after PBSCT with reduced conditioning had the poorest survival estimate with 58 Ϯ 20%, which probably reflects a negative selection for this patient subset. The best survival estimate was found in patients after CD34
ϩ PBSCT with a 100% survival estimate and this was significantly superior to all other transplant procedures (P Ͻ 0.05) (Figure 3 ).
In 21 of 28 patients with cytogenetic or hematologic relapse a molecular remission had been successfully reinduced by either CsA withdrawal (n = 5), donor leukocyte transfusions (DLI) (n = 4), interferon-alfa therapy (n = 2), or combinations of these approaches (n = 7). Three patients have been successfully retransplanted, and three patients are scheduled for retransplantation. Two other patients are currently being treated with interferon-alfa. Two patients died from CML after developing an extramedullary relapse ( Table 2) .
Chimerism analyses
Chimerism analyses had been performed in 76 patients 1 month post transplant and in 72 patients 3 months post transplant. One month post transplant, complete chimerism was found in 16 of 35 (46%) patients after BMT and six of nine (67%) patients after CD34
ϩ PBSCT vs 18 of 24 (75%) patients after PBSCT, and five of eight (63%) patients after PBSCT with reduced conditioning (NS). Three months post transplant, patients after CD34 ϩ PBSCT and BMT had rates of complete chimerism of 55% and 58% (19 of 33 patients), respectively, whereas patients after PBSCT and PBSCT with reduced conditioning had a rate of 86% (19 of 22 patients) and 88% (seven of eight patients), respectively (P Ͻ 0.05).
Discussion
This is the first study which compared the antileukemic effect of PBSCT after reduced conditioning and the transplantation of highly purified CD34 ϩ stem cells to BMT and PBSCT after myeloablative conditioning by evaluating MRD and chimerism at 1 and 3 months post transplant. MRD was analyzed by sequentially performed bcr-abl-PCR assays and cbf␤-myh 11-PCR assays. We defined a molecular relapse (MR) as the detection of at least two consecutive positive PCR assays within a 4-week interval, because this approach has been shown to be more predictive with regard to post-transplant leukemic relapse than single positive PCR results [3] [4] [5] and seemed to be predictive also for AML patients with cbf␤-myh11 transcripts. 13 As the first finding, the present study shows that patients after CD34
ϩ PBSCT have the highest risk of developing a MR of all analyzed transplant methods followed by patients after BMT. In contrast, patients after PBSCT as well as patients after PBSCT with reduced conditioning had a lower risk for a molecular relapse. The 2-year estimate (ϩ standard error) of MR was 100 ϩ 30% for patients after CD34
ϩ PBSCT and 41 Ϯ 8% for patients after BMT (P Ͻ 0.03), whereas the risk of MR was 5 Ϯ 4% for patients after PBSCT (P Ͻ 0.001) and 20 Ϯ 18% for patients after PBSCT with reduced conditioning (NS). Multivariate analysis in our study confirmed that patients after CD34 ϩ PBSCT had a significantly higher risk (two times) for the occurrence of a MR than patients after BMT (P Ͻ 0.03), whereas patients after unmanipulated PBSCT had a significantly lower risk (eight times) for the occurrence of a MR post transplant (P Ͻ 0.001) compared to patients after BMT.
No significant differences were found in the occurrence of a cytogenetic relapse between patients after BMT and patients after CD34
ϩ PBSCT, whereas patients after PBSCT and patients after PBSCT with reduced conditioning had a lower risk for a cytogenetic relapse. The rate of cytogenetic relapse in patients after BMT in this study (30%) is slightly higher than has been described in most larger series of chronic phase CML patients after unmanipulated sibling donor BMT (15-25%).
However, the disadvantage of the lower antileukemic effect of CD34 ϩ PBSCT might be counterbalanced by a very low treatment-related mortality. Thus, all 16 patients are currently alive after CD34
ϩ PBSCT with follow-up at a median of 15 months, whereas the survival rates 3 years post transplant for BMT, PBSCT and PBSCT with reduced conditioning were 65%, 63% and 58%, respectively. Furthermore, four of the five patients with a cytogenetic relapse or engraftment failure were successfully treated by donor leukocyte transfusions (n = 3) or a second transplant (n = 1) and survive free of disease.
The high rate of MR observed after highly purified CD34 ϩ PBSCT is not surprising and may be caused by the T cell depletion of the graft. Because donor T cells are the most important effector cells of graft-versus-leukemia reactions, transfusions of low numbers of T cells along with CD34 ϩ PBSCT may be associated with a low antileukemic effect against residual leukemic cells. Consequently, a T cell-depleted BMT is also associated with an increased risk for a leukemic relapse compared to T cell non-depleted BMT (40-60% vs 15-25%). 2 Patients in relapse of CML after T cell-depleted BMT have a good response rate towards treatment with DLI and achieve more frequently a complete cytogenetic remission than patients after a T cell non-depleted BMT as shown earlier.
14 Our results of MRD did not differ significantly from those in patients having a T cell-depleted BMT, published by Mackinnon and coworkers, 15 in 1994 with the exception that MR occurred significant later after CD34 ϩ PBSCT at a median of 9 months vs a median at 3 months after T cell-depleted BMT. This difference might be explained by the higher numbers of CD34 ϩ stem cells in the graft of CD34 ϩ PBSCT compared to the graft of T cell-depleted BMT, which might lead to an improved stem cell competition effect, by which a rapidly expanding normal progenitor cell compartment can inhibit or displace residual clonogenic leukemic cells after transplant. Recent reports suggest that higher stem cell doses may reduce the risk of relapse after syngeneic and allogeneic T cell-depleted transplants, 8, 16 but this effect seemed to be sufficient only to achieve but not maintain a molecular remission for patients after CD34
ϩ PBSCT. Comparing studies of chimerism between T cell-depleted PBSCT and T cell-depleted BMT shows that a complete chimerism is attained earlier and more frequently after T cell-depleted PBSCT than T cell-depleted BMT, which might also support the importance of high numbers of progenitor cells in the graft. 17, 18 Accordingly, Wiesneth and coworkers 17 found an increased rate of complete chimerism in patients after T cell-depleted PBSCT compared to patients after T cell-depleted BMT (38 of 39 (97%) vs 24 of 32 (75%) in analyses which were performed between 13 and 120 days after transplant. Moreover, Cornelissen and coworkers 18 described a significantly reduced incidence of relapse in patients after T cell-depleted PBSCT (n = 43) compared to T cell-depleted BMT (n = 435).
Another surprising finding of the present study is the low rates of molecular and cytogenetic relapses after PBSCT with reduced conditioning compared to BMT. The rate for molecular relapse and cytogenetic relapse as well as the rate of complete chimerism 1 and 3 months post transplant did not differ significantly from that of unmanipulated PBSCT as shown above, which is known to have more pronounced antileukemic effect than BMT as published earlier. A high frequency of T cell chimerism of 83% at 100 days after PBSCT with reduced conditioning was also reported by Childs and coworkers 19 which underlines our findings. However, Childs and coworkers used a different conditioning regimen and had lower numbers of CD34 ϩ stem cells in their grafts compared to this study.
Although the number of patients studied who were transplanted with PBSCT with reduced conditioning is low, the data shown here may indicate that the antileukemic effect of allogeneic transplantation is achieved much more with an immune modulating effect of alloreactive cells of the graft than with the cytotoxicity of the conditioning regimens.
The results of chimerism analysis correlate very well with the molecular and cytogenetic results. Patients after BMT and CD34 ϩ PBSCT had the lowest rates of complete chimerism at 3 months after transplant. The chimerism status after allogeneic transplant may be influenced by several factors such as the conditioning regimen, GVHD prophylaxis or treatment, the histocompatibility between recipient and donor, the occurrence of acute or chronic GVHD, T cell depletion of the graft, [20] [21] [22] [23] [24] and type of transplant, as published earlier. 6, 24 Nevertheless, the detection of complete chimerism is associated with a better prognosis in regard to leukemic relapse than mixed chimerism. 6, 15, 24 In conclusion, the present study shows that the new transplant method of CD34 ϩ PBSCT had a favourable outcome with a high rate of survival after transplant and, further, that patients who relapsed after CD34 ϩ PBSCT have a high response rate to donor leukocyte infusions. Furthermore, although we studied only nine patients after PBSCT with reduced conditioning, we had the impression that this transplant method may have a low rate of molecular relapse. However, prospective randomized trials comparing PBSCT and PBSCT with reducing conditionings for patients with CML in first chronic phase are strictly required to further substantiate differences in the antileukemic activity of the two transplant methods.
